AgeX Therapeutics vs NewLimit

AgeX Therapeutics was a BioTime spinout pursuing cell-reprogramming and pluripotent stem-cell therapies for aging; it was reverse-merged into Serina Therapeutics in 2024 and its aging assets were sold to Juvenescence.

Longevity

NewLimit

Epigenetic reprogramming biotech using transcription factors to restore youthful gene expression in aging cells, starting with the liver.

For subscribers

Subscribe for the full comparison

Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.

Already subscribed? Sign in →